653 related articles for article (PubMed ID: 27150250)
1. Cysteamine broadly improves the anti-plasmodial activity of artemisinins against murine blood stage and cerebral malaria.
Moradin N; Torre S; Gauthier S; Tam M; Hawari J; Vandercruyssen K; De Spiegeleer B; Fortin A; Stevenson MM; Gros P
Malar J; 2016 May; 15(1):260. PubMed ID: 27150250
[TBL] [Abstract][Full Text] [Related]
2. Cysteamine, the molecule used to treat cystinosis, potentiates the antimalarial efficacy of artemisinin.
Min-Oo G; Fortin A; Poulin JF; Gros P
Antimicrob Agents Chemother; 2010 Aug; 54(8):3262-70. PubMed ID: 20479197
[TBL] [Abstract][Full Text] [Related]
3. Genetic analysis in mice identifies cysteamine as a novel partner for artemisinin in the treatment of malaria.
Min-Oo G; Gros P
Mamm Genome; 2011 Aug; 22(7-8):486-94. PubMed ID: 21437649
[TBL] [Abstract][Full Text] [Related]
4. Treatment of murine cerebral malaria by artemisone in combination with conventional antimalarial drugs: antiplasmodial effects and immune responses.
Guiguemde WA; Hunt NH; Guo J; Marciano A; Haynes RK; Clark J; Guy RK; Golenser J
Antimicrob Agents Chemother; 2014 Aug; 58(8):4745-54. PubMed ID: 24913162
[TBL] [Abstract][Full Text] [Related]
5. In vitro and in vivo anti-malarial activity of novel harmine-analog heat shock protein 90 inhibitors: a possible partner for artemisinin.
Bayih AG; Folefoc A; Mohon AN; Eagon S; Anderson M; Pillai DR
Malar J; 2016 Dec; 15(1):579. PubMed ID: 27903279
[TBL] [Abstract][Full Text] [Related]
6. Oral artesunate prevents Plasmodium berghei Anka infection in mice.
Gumede B; Folb P; Ryffel B
Parasitol Int; 2003 Mar; 52(1):53-9. PubMed ID: 12543147
[TBL] [Abstract][Full Text] [Related]
7. Controlled release of artemisone for the treatment of experimental cerebral malaria.
Golenser J; Buchholz V; Bagheri A; Nasereddin A; Dzikowski R; Guo J; Hunt NH; Eyal S; Vakruk N; Greiner A
Parasit Vectors; 2017 Mar; 10(1):117. PubMed ID: 28249591
[TBL] [Abstract][Full Text] [Related]
8. Cysteamine, the natural metabolite of pantetheinase, shows specific activity against Plasmodium.
Min-Oo G; Ayi K; Bongfen SE; Tam M; Radovanovic I; Gauthier S; Santiago H; Rothfuchs AG; Roffê E; Sher A; Mullick A; Fortin A; Stevenson MM; Kain KC; Gros P
Exp Parasitol; 2010 Aug; 125(4):315-24. PubMed ID: 20219464
[TBL] [Abstract][Full Text] [Related]
9. Artesunate-erythropoietin combination for murine cerebral malaria treatment.
Bienvenu AL; Ferrandiz J; Kaiser K; Latour C; Picot S
Acta Trop; 2008 May; 106(2):104-8. PubMed ID: 18359468
[TBL] [Abstract][Full Text] [Related]
10. Efficacy and safety evaluation of a novel trioxaquine in the management of cerebral malaria in a mouse model.
Odhiambo OC; Wamakima HN; Magoma GN; Kirira PG; Malala BJ; Kimani FT; Muregi FW
Malar J; 2017 Jul; 16(1):268. PubMed ID: 28673299
[TBL] [Abstract][Full Text] [Related]
11. The chemotherapy of rodent malaria. LXIII. Drug combinations to impede the selection of drug resistance, part 6: the potential value of chlorproguanil and dapsone in combination, and with the addition of artesunate.
Peters W; Stewart LB; Robinson BL
Ann Trop Med Parasitol; 2005 Jul; 99(5):457-72. PubMed ID: 16004705
[TBL] [Abstract][Full Text] [Related]
12. Efficacy of intranasal administration of artesunate in experimental cerebral malaria.
Marijon A; Bonnot G; Fourier A; Bringer C; Lavoignat A; Gagnieu MC; Bienvenu AL; Picot S
Malar J; 2014 Dec; 13():501. PubMed ID: 25516091
[TBL] [Abstract][Full Text] [Related]
13. Characterising the effect of antimalarial drugs on the maturation and clearance of murine blood-stage Plasmodium parasites in vivo.
Khoury DS; Cromer D; Elliott T; Soon MSF; Thomas BS; James KR; Best SE; Aogo RA; Engel JA; Gartlan KH; Akter J; Sebina I; Haque A; Davenport MP
Int J Parasitol; 2017 Dec; 47(14):913-922. PubMed ID: 28864033
[TBL] [Abstract][Full Text] [Related]
14. In vivo validation of anti-malarial activity of crude extracts of Terminalia macroptera, a Malian medicinal plant.
Haidara M; Haddad M; Denou A; Marti G; Bourgeade-Delmas S; Sanogo R; Bourdy G; Aubouy A
Malar J; 2018 Feb; 17(1):68. PubMed ID: 29402267
[TBL] [Abstract][Full Text] [Related]
15. Synergistic anti-malarial action of cryptolepine and artemisinins.
Forkuo AD; Ansah C; Boadu KM; Boampong JN; Ameyaw EO; Gyan BA; Arku AT; Ofori MF
Malar J; 2016 Feb; 15():89. PubMed ID: 26879905
[TBL] [Abstract][Full Text] [Related]
16. Interaction between rifampicin, amodiaquine and artemether in mice infected with chloroquine resistant Plasmodium berghei.
Badejo JA; Abiodun OO; Akinola O; Happi CT; Sowunmi A; Gbotosho GO
Malar J; 2014 Aug; 13():299. PubMed ID: 25091936
[TBL] [Abstract][Full Text] [Related]
17. Slow and continuous delivery of a low dose of nimodipine improves survival and electrocardiogram parameters in rescue therapy of mice with experimental cerebral malaria.
Martins YC; Clemmer L; Orjuela-Sánchez P; Zanini GM; Ong PK; Frangos JA; Carvalho LJ
Malar J; 2013 Apr; 12():138. PubMed ID: 23617605
[TBL] [Abstract][Full Text] [Related]
18. Synthesis of artemiside and its effects in combination with conventional drugs against severe murine malaria.
Guo J; Guiguemde AW; Bentura-Marciano A; Clark J; Haynes RK; Chan WC; Wong HN; Hunt NH; Guy RK; Golenser J
Antimicrob Agents Chemother; 2012 Jan; 56(1):163-73. PubMed ID: 22006004
[TBL] [Abstract][Full Text] [Related]
19. Profiling of the anti-malarial drug candidate SC83288 against artemisinins in Plasmodium falciparum.
Duffey M; Sanchez CP; Lanzer M
Malar J; 2018 Mar; 17(1):121. PubMed ID: 29558913
[TBL] [Abstract][Full Text] [Related]
20. The novel ETA receptor antagonist HJP-272 prevents cerebral microvascular hemorrhage in cerebral malaria and synergistically improves survival in combination with an artemisinin derivative.
Dai M; Freeman B; Bruno FP; Shikani HJ; Tanowitz HB; Weiss LM; Reznik SE; Stephani RA; Desruisseaux MS
Life Sci; 2012 Oct; 91(13-14):687-92. PubMed ID: 22820174
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
